Helus Pharma Reports Recent Business Highlights and Fiscal Year 2026 Financial Results

Impact · against what's priced in

Helus Pharma is entering a high-catalyst period with a strengthened balance sheet and clear timelines for its lead asset. The combination of a $50M capital raise, positive signal detection for HLP004, and the confirmed Q4 2026 readout for HLP003 provides a concrete path toward potential commercialization.

HELP+0.60

No priced-in read yet